Cowen Starts Stock Coverage on Supernus Pharmaceuticals (SUPN)

By admin | 6 years ago

Equities researchers at Cowen assumed coverage on shares of Supernus Pharmaceuticals (NASDAQ: SUPN) in a report issued on Tuesday. The firm set an “outperform” rating on the stock.

Shares of Supernus Pharmaceuticals traded down 4.13% during mid-day trading on Tuesday, hitting $5.80. Supernus Pharmaceuticals has a one year low of $5.16 and a one year high of $7.01. The company has a market cap of $138.7 million and a P/E ratio of 0.19.

A number of other analysts have also recently weighed in on SUPN. Analysts at Stifel Nicolaus initiated coverage on shares of Supernus Pharmaceuticals in a research note to investors on Tuesday. They set a “buy” rating and a $15.00 price target on the stock. Analysts at Citigroup (NYSE: C) initiated coverage on shares of Supernus Pharmaceuticals in a research note to investors on Tuesday. They set a “neutral” rating and a $6.00 price target on the stock.

Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

About the author